<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parmax Pharma Ltd has filed an initial disclosure with BSE confirming that it does not qualify as a Large Corporate under SEBI regulations. The company states it does not meet the applicability criteria outlined in SEBI circulars dated November 26, 2018, and October 19, 2023, regarding debt securities issuance and disclosure requirements for Large Corporates. This is a standard compliance filing submitted to the Department of Corporate Services at BSE Limited. The disclosure is signed by the Company Secretary and Managing Director of Parmax Pharma Ltd.
This filing confirms Parmax Pharma is a smaller entity outside Large Corporate classification, meaning it faces lighter regulatory disclosure requirements related to debt securities. This is neutral for shareholders as it simply clarifies the company's compliance status.